Tarloxitinib puts tumor-seeking tail on anti-EGFR drug to precisely target lung cancer

By pairing an anti-EGFR drug with a 'tail' that only activates the drug when it is very near tumor cells, tarloxitinib brings the drug to tumors while keeping concentrations safe in surrounding tissues, new research suggests.